- Home
- CLPT vs PROK Comparison
CLPT vs PROK Comparison
Compare CLPT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | PROK |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.5M | 359.1M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLPT | PROK |
|---|---|---|
| Price | $18.48 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $7.40 |
| AVG Volume (30 Days) | 845.7K | ★ 876.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | $893,000.00 |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.78 | ★ 1075.00 |
| 52 Week Low | $8.27 | $0.54 |
| 52 Week High | $30.10 | $7.13 |
Technical Indicators
Market Signals| Indicator | CLPT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 72.26 | 55.41 |
| Support Level | $12.87 | $1.73 |
| Resistance Level | $27.64 | $1.96 |
| Average True Range (ATR) | 1.29 | 0.12 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 88.14 | 74.60 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.